The OPEN MINDS Executive Blueprint for Crisis ManagementBuilding Organizational Sustainability & Success in a Disrupted Health & Human Service Market
A 32-week program designed to help executive teams navigate the business, organizational, operational, and culture changes of a market in turbulence. The program, based on the seven-component OPEN MINDS executive blueprint, combines a series of 35 live educational web briefings with online technical assistance and a suite of on-demand resources.
Otsuka Collaborates With Magellan Health To Launch ABILIFY MYCITE®
On August 30, 2018 Otsuka America Pharmaceutical, Inc. (Otsuka) announced that it will collaborate with Magellan Health to bring the ABILIFY MYCITE® drug system to the United States. The ABILIFY MYCITE® system is a drug-device combination that is approved by the U.S. Food and Drug Administration (FDA). ABILIFY MYCITE® is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, and for use as an add-on treatment for depression in adults. The system consists of the pill, a patch, an app for the consumer, and tools for health care . . .